Secondary mycosis in surgery: Treatment with fluconazole
- 1 March 1989
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 17 (2) , 111-117
- https://doi.org/10.1007/bf01646895
Abstract
Together with the severity of the underlying disease, mycotic infections are assuming increasing significance in surgical patients under intensive care. 26 patients with severe internal mycotic infections were treated with fluconazole in an open clinical trial. The pathogens isolated wereCandida albicans in 22 cases,Candida tropicalis in four,Torulopsis glabrata in three,Candida parapsilosis in two andAspergillus fumigatus in one. Mixed infections were found in five cases. Most of this series of surgical patients had a severe, life-threatening post-operative condition. Their mean classification by the Apache score was 15.35. The most frequent risk factors were previous injuries to intraabdominal hollow organs and extensive antibiotic therapy; and the peritoneum was, therefore, the commonest site of infection. Antimycotic therapy was with fluconazole at a dose of 200–400 mg daily for at least ten days. The mycosis was cured in 22 of the 26 patients, one of these being a case of severe mycotic peritonitis. Nine patients died of the underlying disease within four weeks of the beginning of treatment. Fluconazole was effective and well tolerated in the treatment of severe life-threatening infections in surgical patients. Mit der Schwere der Grunderkrankung gewinnen begleitende Pilzinfektionen bei chirurgisch, intensivmedizinisch betreuten Patienten zunehmend an Bedeutung. In einer Studie wurden 26 Patienten wegen einer schweren, inneren Mykose mit Fluconazol behandelt. Als Erreger wurden isoliert:Candida albicans (n=22),Candida tropicalis (n=4),Torulopsis glabrata (n=3),Candida parapsilosis (n=2) undAspergillus fumigatus (n=1). In fünf Fällen lag eine Mischinfektion vor. Das chirurgische Krankengut zeigte im postoperativen Zustand ein zumeist lebensbedrohliches Krankheitsbild. Die Klassifizierung nach dem Apache-Score ergab einen Mittelwert von 15,35. Häufigste Risikofaktoren waren vorangegangene Verletzungen intraabdomineller Hohlorgane und eine ausgiebige antibiotische Therapie. Das Peritoneum war deshalb die bevorzugte Lokalisation. Die Therapie der Mykosen erfolgte mit Fluconazol in der Dosierung 200–400 mg/d über mindestens zehn Tage. 22 von 26 Patienten konnten von der Mykose geheilt werden, darunter ein Patient mit einer ausgeprägten Candidaperitonitis. Neun Patienten verstarben bis zu vier Wochen nach Beginn der Therapie an ihrer Grunderkrankung. Fluconazol ist in der Behandlung lebensbedrohlicher, schwerer Pilzinfektionen in der Chirurgie gut wirksam und verträglich.This publication has 15 references indexed in Scilit:
- Etiologic Organisms as Independent Predictors of Death and Morbidity Associated with Bloodstream InfectionsThe Journal of Infectious Diseases, 1987
- Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbitsAntimicrobial Agents and Chemotherapy, 1986
- Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humansAntimicrobial Agents and Chemotherapy, 1985
- Candida Infections in Surgical Patients Dose Requirements and Toxicity of Amphotericin BAnnals of Surgery, 1982
- APACHE—acute physiology and chronic health evaluation: a physiologically based classification systemCritical Care Medicine, 1981
- Kreuzreaktionen von 8 Sprosspilzarten und ihre Bedeutung für die serologische Candida DiagnostikMedical Microbiology and Immunology, 1979
- Infections caused by arterial catheters used for hemodynamic monitoringThe American Journal of Medicine, 1979
- Hospital-acquired fungemiaThe American Journal of Medicine, 1979
- Venous catheter-associated candidemiaThe Lancet Healthy Longevity, 1978
- The risk of positive cultures for Candida in the critically ill patientCritical Care Medicine, 1978